Explainable AI for pharma
MedInsights is a Paris-born biotech company accelerating drug discovery and repurposing through knowledge-graph-based explainable AI. We provide the biologically traceable logic pharmaceutical leaders demand to de-risk clinical success.
A product-suite trace groups the four MedInsights products into decision paths, then moves from a product question to evidence context and a traceable brief.
Illustrative interface only. It contains no real organizations, people, patient records, or confidential programs.
Assistance Publique – Hôpitaux de Paris
CHU de Saint-Étienne
Grenoble Institut des Neurosciences
Institut Necker Enfants Malades
Institut Imagine
Karolinska Institutet
Karolinska University Hospital
National University of Singapore
Université Paris Cité
BariaTek
Bayer
HuntX Pharma
Ipsen
Reventus
Agnosci
CubaseBio
pixlbio
PSC Biotech
Repurgenesis
VitroscopeProduct suite
Move from the homepage into product paths for mechanism qualification, translational reasoning, phenotype context, and portfolio prioritization.
Unify your transcriptomics, proteomics, epigenomics and metabolomics datasets into an automated network pharmacology workflow. Dynamically simulate drug responses on static digital twins to pinpoint exactly where therapeutic compensation ends and adverse toxicity begins, De-risk your mechanism of action before wasting millions in the wet lab.
BD use: Turn disconnected multi-omics data into clear, contextual causality
Eliminate guesswork by using deep learning to optimize inclusion criteria, map endpoints, and engineer protocols around failure bottlenecks. Cut evaluation costs from $2.5M to under $1M while compressing mapping and intelligence timelines from months to days. Protect patent life and stop costly delays by converting global trial data into predictive foresight for waiting patients.
BD use: Stop navigating the clinical landscape in the dark
Eliminate the translational blind spot by matching the exact animal model to your target human disease phenotype. Stop wasting $5–10 billion annually on compounds that work perfectly in mice but fail in human clinical trials. Automatically flag opposing phenotypes between rodents and humans to ensure preclinical success dictates clinical reality.
BD use: Ensure your preclinical success dictates human clinical reality
Stop using chatbots that summarize one paper at a time. Run complex, parallel research queries that automatically build complete literature and systematic reviews. Eliminate the dangerous risk of unverified AI claims. Every line of generated text is bound under rigid constraints to traceable PMIDs and DOIs. Move past basic search engines to a platform that finishes assigned research tasks, delivering structured outputs straight into Word, Excel, and figures.
BD use: Turn massive literature search into immediate, actionable discovery
Mechanism-value framing
MedInsights positions NEXUS-Rx as the explainable AI and knowledge graph engine behind product-suite conversations, so BD and licensing teams can review the reasoning before moving into deeper follow-up.
For pharma BD and licensing teams, the MedInsights story is not a generic AI tools catalogue. It is a structured path from mechanism qualification and asset evaluation to translational reasoning and partner discussion materials.
France Biotech
France Digitale
Paris Biotech Santé
RePo4EU
BNP Paribas
Bpifrance
Eureka Eurostars
Google Workspace
Scaleway